Abstract | AIM: METHODS: Step I. For patients with SHPT (200 ≤ iPTH ≤ 500 pg/ml), a dose of 2.5 mg maxacalcitol (OCT) was administered intravenously three times a week with oral sevelamer hydrochloride; the dose was increased to a 10 µg maximum three times a week to control iPTH to < 150 pg/ml. Step II. When iPTH reached the target level, patients were assigned to Group A (oral alfacalcidol 1.0 µg/day) or B (oral alfacalcidol 0.25 µg/ day). Serum iPTH, calcium, and inorganic phosphorus were measured each month for 6 months. Maintenance rates for the target iPTH levels were evaluated, < 150 pg/ml at Step I and < 200 pg/ml at Step II. RESULTS: iPTH decreased to < 150 pg/ml by OCT in 24 of 35 patients (68.6%). During the 24-week observation period, iPTH was controlled for 83.3% patients in Group A vs. 36.4% for Group B (p < 0.05). No dropouts due to hypercalcemia or hyperphosphatemia occurred. CONCLUSION: OCT dose titration was effective for SHPT. A higher daily dose of oral alfacalcidol (1.0 µg) appears to be more effective than a lower dose (0.25 µg) as maintenance therapy after iPTH control.
|
Authors | M Adachi, T Miyoshi, N Shiraishi, H Shimada, S Sakaguchi, K Tomita, K Kitamura |
Journal | Clinical nephrology
(Clin Nephrol)
Vol. 76
Issue 4
Pg. 266-72
(Oct 2011)
ISSN: 0301-0430 [Print] Germany |
PMID | 21955861
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers
- Bone Density Conservation Agents
- Polyamines
- Sevelamer
- Calcitriol
- maxacalcitol
|
Topics |
- Administration, Oral
- Aged
- Biomarkers
(blood)
- Bone Density Conservation Agents
(administration & dosage, therapeutic use)
- Calcitriol
(administration & dosage, analogs & derivatives, therapeutic use)
- Female
- Humans
- Hyperparathyroidism, Secondary
(drug therapy)
- Infusions, Intravenous
- Male
- Polyamines
(administration & dosage, therapeutic use)
- Prospective Studies
- Renal Dialysis
- Sevelamer
- Statistics, Nonparametric
- Treatment Outcome
|